Dingfu Biotarget Co., Ltd.

Shihuida Pharmaceutical Group (Jilin) Co., Ltd.

Kai Fu

Ting Xu

Yan Luan

Jianjian Peng

Shilong Fu

Xiaoxiao Wang

Hui Ma

Meng Zhao

Shuli Ma

Xiaolong Pan

Jian Ding

Xin Zhang

Xiaojuan Liu

Songbing Qin

An antibody may be capable of specifically binding CD137 or an antigen binding fragment thereof, wherein the light chain variable region and the heavy chain variable region have one or more mutations. The antibody or antigen binding fragment thereof may be used in preparing a drug. The antibody or an antigen binding fragment thereof may specifically bind CD137, and may include a light chain variable region VL and a heavy chain variable region VH, wherein compared to a sequence as shown in SEQ ID NO: 103, the VL comprises one or more VL amino acid mutations, and the VL amino acid mutation occurs at one or more positions: V3, A10, K44, D71, and/or V77.

Anti-CD137 antibodies and method of treating colorectal cancer using them

Provided are compositions and methods for treating cancer comprising the use of a immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy. The immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy shows synergistic effects in cancer treatment.

Methods and compositions for cancer treatment

Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Proteinaceous heterodimer and use thereof

The present disclosure provides an antibody, or an antigen binding fragment or variant thereof, which binds to CD27 and exhibits at least one of the following properties: specifically binds to CD27 with a Kof 10M or less; activates and/or increases CD27 mediated NF-&#x3ba;B activity; stimulates CD4and/or CD8T cell proliferation; binds to human CD27 expressed on a cell surface; stimulates secretion of IFN-&#x3b3; by CD4and/or CD8T cells. The present disclosure also provides a method for preparing and using said antibody.

Anti-CD27 antibodies and use thereof

Provided is an immunoconjugate useful in inhibiting tumor growth, and a composition and/or protein mixture comprising the immunoconjugate. Also provided are methods for the production of the immunoconjugate, as well as pharmaceutical uses of the immunoconjugate in inhibiting tumor growth, including but not limited to treatment of cancers.

Immunoconjugates comprising signal regulatory protein alpha

Growing community of inventors

Suzhou, China

Kai Fu